Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?

Altres autors/es

Institut Català de la Salut

[Dopazo C, Charco R] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2023-08-30T10:11:42Z

2023-08-30T10:11:42Z

2023-03-29



Resum

Perihilar cholangiocarcinoma; Liver transplantation; Outcomes


Colangiocarcinoma perihilar; Trasplantament hepàtic; Resultats


Colangiocarcinoma perihiliar; Trasplante hepático; Resultados


Perihilar cholangiocarcinoma (pCCA) is a challenging disease with limited options. Surgical resection and adjuvant therapy remain the only established treatment for those with resectable disease. Since the publication of the Mayo protocol in 2000, neoadjuvant chemoradiation and liver transplantation have become the standard of care in selected patients with unresectable de novo pCCA or resectable pCCA arising under primary sclerosing cholangitis. However, its application is diverse worldwide, and the need for donor organs is one of the main limitations. Also, differences in the neoadjuvant regimen used were observed. In this review, we discuss the latest results of this approach, the recommended tools for diagnostic work-up, and advances in systemic therapy to improve patient selection and long-term survival.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

OAE Publishing

Documents relacionats

Hepatoma Research;9

http://dx.doi.org/10.20517/2394-5079.2022.75

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)